

## Title (en)

DIHYDROPYRIDINE COMPOUNDS, THEIR PRODUCTION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

## Publication

**EP 0167371 A3 19870616 (EN)**

## Application

**EP 85304646 A 19850628**

## Priority

JP 13365084 A 19840628

## Abstract (en)

[origin: EP0167371A2] The invention provides a dihydropyridine compound of the following general formula (I) or a salt thereof: <CHEM> wherein R<1> and R<2> are the same or different and selected from C1, to C10 alkyl groups, C1 to C5 alkyl groups interrupted by oxygen atom(s), and C1 to C5 alkyl groups substituted by C3 to C6 alicyclic group(s); R<3> and R<4> are the same or different C1 to C5 alkyl groups; R<3> and R<4> are the same or different and selected from hydrogen and halogen atoms and nitro, C1 to C5 alkyl, C1 to C5 alkoxy, C1 to C5 alkylthio, C1 to C5 alkylsulfonyl and C1 to C5 alkylsulfinyl groups; R<7> and R<8> are the same or different and are selected from hydrogen and halogen atoms and cyano, C1 to C5 alkoxy and C1 to C5 alkanoylamino groups or combine to form, with the adjacent phenyl group, a naphthyl group; A represents a single bond, or a vinylene (-CH=CH-) or ethynylene group (-C≡C-); B represents a single bond or -CH<sub>2</sub>O-; and m and n are the same or different and selected from 0 and integers of 1 to 5, and methods of making such a compound. The compounds may be used for treatment or prevention of ischemic heart-disease and cardiovascular disorders and may show both Ca<sup>2+</sup> antagonistic action and adrenergic betareceptor blocking activity.

## IPC 1-7

**C07D 211/90; A61K 31/44; C07D 401/12**

## IPC 8 full level

**C07D 211/82** (2006.01); **A61K 31/44** (2006.01); **A61K 31/455** (2006.01); **A61P 9/00** (2006.01); **A61P 9/06** (2006.01); **A61P 9/08** (2006.01); **A61P 9/10** (2006.01); **A61P 9/12** (2006.01); **A61P 25/02** (2006.01); **A61P 25/28** (2006.01); **C07C 323/22** (2006.01); **C07D 211/90** (2006.01); **C07D 401/12** (2006.01); **C07C 317/24** (2006.01)

## CPC (source: EP KR US)

**A61P 9/00** (2017.12 - EP); **A61P 9/06** (2017.12 - EP); **A61P 9/08** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 9/12** (2017.12 - EP); **A61P 25/02** (2017.12 - EP); **A61P 25/28** (2017.12 - EP); **C07C 317/00** (2013.01 - EP US); **C07C 323/00** (2013.01 - EP US); **C07D 211/82** (2013.01 - KR); **C07D 211/90** (2013.01 - EP US); **C07D 401/12** (2013.01 - EP US)

## Citation (search report)

- [E] EP 0179386 A2 19860430 - BAYER AG [DE]
- [A] EP 0101023 A1 19840222 - BANYU PHARMA CO LTD [JP]
- [A] EP 0071819 B1 19870422
- [A] EP 0011706 A1 19800611 - BAYER AG [DE]
- [A] EP 0002231 A1 19790613 - BAYER AG [DE]

## Cited by

EP0297613A3; EP0194751A1; US4873254A; EP0276552A1; EP0194047A1; WO9213839A1

## Designated contracting state (EPC)

AT BE CH DE FR GB IT LI LU NL SE

## DOCDB simple family (publication)

**EP 0167371 A2 19860108; EP 0167371 A3 19870616; EP 0167371 B1 19910306**; AT E61356 T1 19910315; AU 4396785 A 19860102; AU 569161 B2 19880121; CA 1300157 C 19920505; CA 1312085 C 19921229; DE 3581967 D1 19910411; ES 544647 A0 19870901; ES 552335 A0 19870416; ES 552336 A0 19870416; ES 8704898 A1 19870416; ES 8704899 A1 19870416; ES 8707933 A1 19870901; GR 851568 B 19851125; JP H0123463 B2 19890502; JP S6112662 A 19860121; KR 860000261 A 19860127; KR 900005019 B1 19900718; MX 26687 A 19940331; MX 7533 E 19890815; PT 80714 A 19850701; PT 80714 B 19861211; SU 1342413 A3 19870930; US 4727082 A 19880223

## DOCDB simple family (application)

**EP 85304646 A 19850628**; AT 85304646 T 19850628; AU 4396785 A 19850621; CA 485923 A 19850628; CA 571338 A 19880706; DE 3581967 T 19850628; ES 544647 A 19850627; ES 552335 A 19860224; ES 552336 A 19860224; GR 850101568 A 19850626; JP 13365084 A 19840628; KR 850004583 A 19850627; MX 1159585 U 19850628; MX 2668788 A 19880720; PT 8071485 A 19850626; SU 3915847 A 19850627; US 90835086 A 19860917